302 related articles for article (PubMed ID: 30501012)
41. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
42. [Fibrodysplasia ossificans progressiva. Report of one case].
Contreras-Olea O; Goecke-Hochberger C; Rumié-Carmi HK; Lobo-Avilés R; Mellado-Sagredo C; Avila-Smirnow D
Rev Med Chil; 2019 Mar; 147(3):384-389. PubMed ID: 31344178
[TBL] [Abstract][Full Text] [Related]
43. Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva.
Nikishina IP; Arsenyeva SV; Matkava VG; Arefieva AN; Kaleda MI; Smirnov AV; Blank LM; Kostik MM
Pediatr Rheumatol Online J; 2023 Aug; 21(1):92. PubMed ID: 37644581
[TBL] [Abstract][Full Text] [Related]
44. ACVR1
Haupt J; Stanley A; McLeod CM; Cosgrove BD; Culbert AL; Wang L; Mourkioti F; Mauck RL; Shore EM
Mol Biol Cell; 2019 Jan; 30(1):17-29. PubMed ID: 30379592
[TBL] [Abstract][Full Text] [Related]
45. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
[TBL] [Abstract][Full Text] [Related]
46. Molecular characterization of known and novel ACVR1 variants in phenotypes of aberrant ossification.
Gupta A; Zimmermann MT; Wang H; Broski SM; Sigafoos AN; Macklin SK; Urrutia RA; Clark KJ; Atwal PS; Pignolo RJ; Klee EW
Am J Med Genet A; 2019 Sep; 179(9):1764-1777. PubMed ID: 31240838
[TBL] [Abstract][Full Text] [Related]
47. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
Pacifici M
Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
[TBL] [Abstract][Full Text] [Related]
48. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
[TBL] [Abstract][Full Text] [Related]
49. The effect of Activin-A on periodontal ligament fibroblasts-mediated osteoclast formation in healthy donors and in patients with fibrodysplasia ossificans progressiva.
Schoenmaker T; Wouters F; Micha D; Forouzanfar T; Netelenbos C; Eekhoff EMW; Bravenboer N; de Vries TJ
J Cell Physiol; 2019 Jul; 234(7):10238-10247. PubMed ID: 30417373
[TBL] [Abstract][Full Text] [Related]
50. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.
Wang H; Kaplan FS; Pignolo RJ
Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397384
[TBL] [Abstract][Full Text] [Related]
51. Periodontal ligament fibroblasts as a cell model to study osteogenesis and osteoclastogenesis in fibrodysplasia ossificans progressiva.
de Vries TJ; Schoenmaker T; Micha D; Hogervorst J; Bouskla S; Forouzanfar T; Pals G; Netelenbos C; Eekhoff EMW; Bravenboer N
Bone; 2018 Apr; 109():168-177. PubMed ID: 28705683
[TBL] [Abstract][Full Text] [Related]
52. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
53. Identification of the Identical Human Mutation in
Casal ML; Engiles JB; Zakošek Pipan M; Berkowitz A; Porat-Mosenco Y; Mai W; Wurzburg K; Xu MQ; Allen R; ODonnell PA; Henthorn PS; Thompson K; Shore EM
Vet Pathol; 2019 Jul; 56(4):614-618. PubMed ID: 31007133
[TBL] [Abstract][Full Text] [Related]
54. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of TGFβ signaling decreases osteogenic differentiation of fibrodysplasia ossificans progressiva fibroblasts in a novel in vitro model of the disease.
Micha D; Voermans E; Eekhoff MEW; van Essen HW; Zandieh-Doulabi B; Netelenbos C; Rustemeyer T; Sistermans EA; Pals G; Bravenboer N
Bone; 2016 Mar; 84():169-180. PubMed ID: 26769004
[TBL] [Abstract][Full Text] [Related]
56. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.
Barruet E; Morales BM; Cain CJ; Ton AN; Wentworth KL; Chan TV; Moody TA; Haks MC; Ottenhoff TH; Hellman J; Nakamura MC; Hsiao EC
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429363
[TBL] [Abstract][Full Text] [Related]
57. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
58. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.
Cappato S; Giacopelli F; Ravazzolo R; Bocciardi R
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587443
[TBL] [Abstract][Full Text] [Related]
59. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
